復星醫藥(02196.HK)斥2.49億人幣購聯合健康險14%股權
復星醫藥(02196.HK)公布,與順德科創集團及聯合健康險簽訂股份認購協議終止合同,據此,各方同意終止履行原股份認購協議,並由聯合健康險向公司及順德科創集團全額返還已支付的認購出資款及約定利息。
同日,集團與南沙科金將增資聯合健康險。根據新股份認購協議,公司及南沙科金擬各自出資2.49億元人民幣以分別認購聯合健康險新增股份9,722萬股。增持後,雙方均持有聯合健康險14%股份,為第三大股東。
集團指,本次增資所得款項擬用於聯合健康險補充資本金,以提高償付能力和承保能力,並進一步擴大業務規模。本次增資將有利於推動集團醫藥、醫療健康服務等業務與商業保險的合作融通,進一步探索模式創新、加深業務協同。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.